Effervescent Or Pressurized Fluid Containing Patents (Class 424/43)
-
Patent number: 6645466Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.Type: GrantFiled: August 9, 2001Date of Patent: November 11, 2003Assignee: Jago Research AGInventors: Manfred Keller, Rudi Müller-Walz
-
Patent number: 6638495Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.Type: GrantFiled: May 21, 2001Date of Patent: October 28, 2003Assignee: Nektar TherapeuticsInventors: Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
-
Patent number: 6632419Abstract: The libido of adult human female patients is increased by the bolus delivery of a testosterone which is preferably dihydrotestosterone. The formulation is preferably aerosolized and inhaled into a patient's lungs where particles of testosterone deposits on lung tissue and then enter the patient's circulatory system. The patient's testosterone level is quickly enhanced well above baseline levels for a short period and subsides to baseline levels with normal metabolism thereby providing desired short term effects on enhanced libido without undesirable effects of long term enhanced testosterone levels. Additional formulations are provided including formulations for aerosolized delivery of sildenafil citrate which are delivered to male or female patients.Type: GrantFiled: March 19, 2001Date of Patent: October 14, 2003Assignees: Aradigm CorporationInventors: Reid M. Rubsamen, Robert Cole
-
Publication number: 20030190286Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: October 9, 2003Inventor: Harry A. Dugger
-
Publication number: 20030190287Abstract: A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.Type: ApplicationFiled: May 12, 2003Publication date: October 9, 2003Applicant: Chiesi Farmaceutici S.p.A.Inventors: David Lewis, Davis Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
-
Patent number: 6630466Abstract: The present invention relates to new medicament compositions based on anticholinergic compounds, which have a long-lasting effect, and salmeterol, processes for their production and their use in the therapy of respiratory ailments.Type: GrantFiled: February 14, 2002Date of Patent: October 7, 2003Assignee: Boehringer Ingelheim Pharma KGInventors: Karl-Heinz Bozung, Michel Pairet, Richard Reichl, Alexander Walland
-
Publication number: 20030185761Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: October 2, 2003Inventor: Harry A. Dugger
-
Patent number: 6623753Abstract: The invention concerns liposomal preparations comprising as the active agent a compound of formula I in free base form or in acid addition salt form. It also concerns a method of preparation of such liposomal preparations by encapsulating a compound of formula I with an appropriate liposome forming material, a corresponding pharmaceutical compositions, and methods of treatment of systemic, topical and pulmonal fungal infections.Type: GrantFiled: June 24, 1997Date of Patent: September 23, 2003Assignee: Novartis AGInventors: David Bodmer, Thomas Kissel, Friedrich Richter, Harry Tiemessen
-
Patent number: 6613307Abstract: The present invention relates to formulations comprising particulate products which may be prepared by methods and apparatus using supercritical fluids. More particularly, the invention relates to formulations comprising certain crystalline forms of 4-hydroxy-&agr;1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (salmeterol) 1-hydroxy-2-naphthalenecarboxylate (xinafoate). Accordingly, the present invention provides an aerosol pharmaceutical formulation comprising salmeterol xinafoate with a controlled particle size, shape and morphology, and a fluorocarbon, hydrogen-containing fluorocarbon or hydrogen-containing chlorofluorocarbon propellant.Type: GrantFiled: October 5, 2000Date of Patent: September 2, 2003Assignee: SmithKline Beecham CorporationInventor: Simon Murray Cooper
-
Patent number: 6610271Abstract: A therapeutic composition of lorazepam and its pharmaceutically acceptable derivatives are provided for intranasal administration of at least one predetermined volumetric unit dose in the form of a spray by means that delivers one or more therapeutically prescribed unit doses that are highly accurate as to the volume discharged and which leave no significant quantity of the composition in the delivery means.Type: GrantFiled: February 20, 2001Date of Patent: August 26, 2003Assignee: University of Kentucky Research FoundationInventor: Daniel P. Wermeling
-
Patent number: 6610312Abstract: A wiping article is provided which includes an effervescent cleanser composition held within a pouch formed from a first and second substrate sheet. At least one of the substrate sheets must be water permeable. The effervescent composition is an intimate mixture of an acid material such as citric acid and an alkaline material such as sodium bicarbonate. Water contact causes the combination to effervesce. A dry surfactant such as sodium cocoyl isethionate in contact with the water and effervescing carbon dioxide results in a highly pleasant sudsing system. Skin benefit agents may be included within the composition. The effervescent action may improve deposition of the skin benefit agents onto the skin.Type: GrantFiled: February 15, 2001Date of Patent: August 26, 2003Assignee: Unilever Home & Personal Care USA, Division of Conopco, Inc.Inventors: Linda Farrell, Craig Stephen Slavtcheff, Alexander Paul Znaiden, Paul Vinski
-
Patent number: 6608073Abstract: This invention provides a method of rapidly and reliably delivering codeine, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment of pain or cough. The present invention further provides pharmaceutical compositions comprising codeine, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other analgesic and/or antitussive compounds.Type: GrantFiled: October 1, 1999Date of Patent: August 19, 2003Assignee: New Millennium Pharmaceutical Research, Inc.Inventors: Anwar A. Hussain, Lewis W. Dittert, Abeer M. Al-Ghananeem
-
Publication number: 20030152520Abstract: Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided.Type: ApplicationFiled: May 22, 2002Publication date: August 14, 2003Applicant: Neurogen CorporationInventors: Ping GE, Taeyoung Yoon, Lu Yan Zhang, Raymond F. Horvath
-
Patent number: 6605304Abstract: A particle including anions dispersed throughout an amorohous, paracrystalline or crystalline solid solution, the anions being capable of reacting with hydronioum ions to generated a gas. The particle can be incorporated into a power capable of generating and releasing a gas after hydrolysis of an acid releasing agent.Type: GrantFiled: August 21, 1998Date of Patent: August 12, 2003Assignees: Bernard Technologies, Inc., Southwest Research InstituteInventors: Stephen T. Wellinghoff, Joel J. Kampa, Sumner A. Barenberg, Peter N. Gray, Michael D. Lelah
-
Patent number: 6596740Abstract: A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 10 mg/ml. The composition used alone assists in reduction of the desire of a subject to smoke tobacco. It also reduces the nasal symptoms associated with administration of higher concentrations of nicotine to the nasal mucosa.Type: GrantFiled: October 24, 2001Date of Patent: July 22, 2003Inventor: Richard L. Jones
-
Patent number: 6596261Abstract: A method of treating in a human or animal a condition capable of treatment by oral or nasal inhalation has been found. The method comprises administering a medicinal aerosol formulation comprising a selected medicament under conditions where the amount of the selected drug delivered to the site of action, e.g. the lungs, is maximized.Type: GrantFiled: October 30, 2000Date of Patent: July 22, 2003Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Simon Stefanos, Yaping Zhu
-
Patent number: 6589541Abstract: The present invention is a method and apparatus for spraying makeup that masks imperfections in the skin including, but not limited to, freckles, tattoos, birthmarks, scars and post-laser surgery discoloration. The apparatus of the present invention is a hand-held sprayable cosmetic container containing a cosmetic composition that may be a foundation, a shimmer, a bronzer, a glitter, a self-tanning composition, a moisturizer, a toner, a lip color, an eyebrow color, a cheek color and/or an eye color. The apparatus may also be designed to deliver drugs (both prescription and over the counter medicines), deliver vitamins or other skin care compositions, to protect the skin from the sun, treat the skin after exposure to the sun, and/or provide an aromatherapy treatment.Type: GrantFiled: May 18, 2001Date of Patent: July 8, 2003Assignee: Classified Cosmetics, Inc.Inventors: Yolanda Halston, Richard Berg
-
Patent number: 6585957Abstract: A medicinal formulation is disclosed. The formulation comprises (a) a protein or peptide medicament; (b) a fluid carrier for containing said medicament; and a stabilizer selected from an amino acid, a derivative thereof or a mixture of the foregoing.Type: GrantFiled: October 30, 2000Date of Patent: July 1, 2003Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Yaping Zhu, John Z. Sun, Simon Stefanos
-
Patent number: 6585984Abstract: A cosmetic product is provided packaged in a dispenser with separate first and second storage areas. The first of the areas contains a first cosmetic composition containing a first dermal active agent, preferably selected from keratolytic skin agents. Particularly preferred are alpha- and beta-hydroxy carboxylic acids as first dermal active placed in a composition having a pH from about 1 to about 5.5. The second area contains a second cosmetic composition with a second dermal agent incompatible with the first composition. Particularly preferred second dermal agents are retinoids, vitamins, enzymes and anti-oxidants. Most preferred is retinol. The dispenser allows transfer of the first and second compositions through an exit nozzle in a respective dispensing weight ratio of from about 30:1 to about 2:1.Type: GrantFiled: November 16, 2000Date of Patent: July 1, 2003Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.Inventors: Ian Richard Scott, Jonathan David Hague, Dwiwahyu Haryo Suryo, Endah Sulistyowati, Prem Chandar, Ronni Lynn Weinkauf
-
Patent number: 6582729Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.Type: GrantFiled: August 15, 2000Date of Patent: June 24, 2003Assignee: Naktar TherapeuticsInventors: Mohammad Eljamal, John S. Patton, Linda C. Foster, Robert M. Platz
-
Patent number: 6579512Abstract: A pharmaceutical topical spray composition of corticosteroid, an alcohol, a propelant, and isopropyl myristate. A method for treating an inflammatory skin condition using the administration to the skin of a mammal of the pharmaceutical composition. The pharmaceutical composition is effective in the treatment of inflammatory skin conditions without the need for zinc pyrithione, undecylenic acid, or a detergent.Type: GrantFiled: June 15, 2001Date of Patent: June 17, 2003Inventor: Charles E. Crutchfield, III
-
Patent number: 6576810Abstract: A toilet training article in the form of a toilet training pad containing an effervescent agent is disclosed. The toilet training pad, which may be an insertable pad or integrated directly into an undergarment, contains an effervescent agent which releases gas upon being contacted by urine. The effervescent agent may be in the form of a compound containing a substantially inert gas, or may be a combination of compounds that, upon being contacted by urine, produce a gas.Type: GrantFiled: October 25, 2000Date of Patent: June 10, 2003Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Richard L. Underhill, Marsha M. Malone, Bernard J. Minerath, III, Beth A. Lange, Duane G. Krzysik, David W. Koenig, Kimberly M. Bleck
-
Patent number: 6572873Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.Type: GrantFiled: November 22, 2000Date of Patent: June 3, 2003Assignee: BTG International LimitedInventors: Tariq Osman, Sheila Bronwen Flynn, David Dakin Iorwerth Wright, Anthony David Harman, Timothy David Boorman
-
Publication number: 20030099599Abstract: The invention provides a propellant free, non-pressurized spray dispenser containing a suspension of an antibiotic effective for the treatment of group A streptococci for topical application to the throat.Type: ApplicationFiled: November 21, 2002Publication date: May 29, 2003Inventor: Ora Shuval-Sudai
-
Patent number: 6569406Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).Type: GrantFiled: August 7, 2001Date of Patent: May 27, 2003Assignee: Nektar TherapeuticsInventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
-
Publication number: 20030095926Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: May 22, 2003Inventor: Harry A. Dugger
-
Publication number: 20030095927Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: May 22, 2003Inventor: Harry A. Dugger
-
Publication number: 20030095925Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: May 22, 2003Inventor: Harry A. Dugger
-
Patent number: 6565833Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a troglitazone medicament and a fluid carrier.Type: GrantFiled: October 31, 2000Date of Patent: May 20, 2003Assignee: Aeropharm Technology IncorporatedInventors: Anthony J. Cutie, Akwete L. Adjei
-
Patent number: 6565885Abstract: Spray drying methods for forming powder compositions for pharmaceutical applications are disclosed. According to one aspect of the invention, the spray drying feed stock comprises a bioactive agent, surfactant, and a blowing agent. Another aspect of the invention is directed to spray drying a feed stock comprising a phospholipid and calcium chloride.Type: GrantFiled: December 22, 1998Date of Patent: May 20, 2003Assignee: Inhale Therapeutic Systems, Inc.Inventors: Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov, Ernest G. Schutt, Luis A. Dellamary
-
Publication number: 20030082107Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: May 1, 2003Inventor: Harry A. Dugger
-
Publication number: 20030077283Abstract: A method for treatment of psoriasis and other inflammatory skin conditions, comprising applying topically a composition containing as active ingredient an antibody neutralizing human Interleukin-8 (IL-8) biological activity together with a pharmaceutically acceptable carrier. The invention also includes a pharmaceutical composition for treating inflammatory skin conditions. The pharmaceutical composition includes antibodies that neutralize human Interleukin-8 (IL-8) biological activity.Type: ApplicationFiled: September 21, 2001Publication date: April 24, 2003Inventor: George Q. W. Ye
-
Publication number: 20030077229Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: April 24, 2003Inventor: Harry A. Dugger
-
Publication number: 20030077227Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: April 24, 2003Inventor: Harry A. Dugger
-
Publication number: 20030077228Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 29, 2002Publication date: April 24, 2003Inventor: Harry A. Dugger
-
Patent number: 6551577Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.Type: GrantFiled: June 23, 1999Date of Patent: April 22, 2003Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Publication number: 20030072716Abstract: A composition is disclosed comprising a carbohydrate-based material a dispersed in carbon dioxide. A general method for synthesizing inexpensive, renewable, non-toxic, non-fluorous, carbohydrate based CO2-philes is disclosed. These CO2-philes are soluble in carbon dioxide. Methods of making the composition are also disclosed. The methods and composition are useful in a variety of applications and can utilize gaseous, liquid and supercritical carbon dioxide. The methods and compositions are useful in the synthesis of surfactants and metal chelates for CO2, as a sizing substrate, in CO2-based coating processes, for impregnation and plasticizing cellulosic and non-cellulosic materials, in pharmaceutical applications, such as crystallization, dispersion and encapsulation of bioactive molecules in solid systems, in the densification of CO2, in the synthesis of biodegradable polymers in CO2, and for carbon dioxide removal, to name just a few.Type: ApplicationFiled: June 21, 2002Publication date: April 17, 2003Inventors: Raveendran Poovathinthodiyil, Scott L. Wallen
-
Patent number: 6548049Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing pioglitazone medicament and a fluid carrier.Type: GrantFiled: October 31, 2000Date of Patent: April 15, 2003Assignee: Aeropharm Technology IncorporatedInventors: Anthony J. Cutie, Akwete L. Adjei, Frederick A. Sexton
-
Publication number: 20030064028Abstract: Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. Precise delivery of nitric oxide at therapeutic levels of 20 to 100 ppm and inhibition of reaction of nitric oxide with oxygen to form toxic impurities such as nitrogen dioxide can provide effective inhalation therapy for pulmonary hypertension.Type: ApplicationFiled: August 28, 2002Publication date: April 3, 2003Inventors: David H. Fine, Stephen J. MacDonald, David Rounbehler, David Wheeler, Jonathan L. Rolfe, George Jarvis
-
Patent number: 6540983Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a &bgr;-cell hypoglycemic agent and a fluid carrier.Type: GrantFiled: October 31, 2000Date of Patent: April 1, 2003Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Anthony J. Cutie, John Z. Sun, Fred Sexton
-
Patent number: 6540982Abstract: This invention relates to a medicinal aerosol formulation and, more particularly, to a medicinal aerosol formulation an insulin combination and a fluid carrier.Type: GrantFiled: October 30, 2000Date of Patent: April 1, 2003Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Anthony J. Cutie
-
Patent number: 6534075Abstract: An antimicrobial and antiviral composition in powder form or in the form of a two part liquid concentrate for washing and sanitizing foods, food surfaces, food ware, process waters, animal quarters, and animal carcasses is described. The composition may also be used to reduce the microbial and viral population on animals; reducing human pathogenic microbes, reducing opportunistic pathogenic microbes on eggs, and treating skin diseases. The composition includes three reactive species which in solution form an oxidizing species, and optionally a food grade acid source. The reactive species include a natural source of a quaternary or protonizable nitrogen compound which is acceptable on foods, an oxidant and a halide source.Type: GrantFiled: March 26, 1999Date of Patent: March 18, 2003Assignee: Ecolab Inc.Inventors: Robert D. P. Hei, Kim R. Smith, Polly D. Laugen, Bruce R. Cords, Shaun P. Kennedy
-
Patent number: 6528040Abstract: An analgesic, anesthetic and antipruritic formulation is provided containing 0.01 to 13 wt % alkyl esters; and 20 to 70 wt % Emu oil; 10 to 33 wt % benzyl alcohol; 10 to 33 wt % benzoin; 0.2 to 2 wt % allantoin; 0.25 to 1.25 wt % methylparaben and 0.01 to 0.30 wt % propylparaben. The formulation may be formulated as a spray or transdermal formula. The formulation may be used for treatment of chronic cutaneous ulcers and burn wounds.Type: GrantFiled: August 24, 2001Date of Patent: March 4, 2003Inventors: Maurine Pearson, Teresa L. Barr
-
Patent number: 6524596Abstract: The invention concerns a cosmetic composition comprising in a cosmetically acceptable aqueous or hydroalcoholic medium, an aqueous dispersion of insoluble styling polymer particles, resulting in a mean fixing energy of styling material after drying on the keratinous fibers less than 200 microjoules in a fixing test. The invention is applicable to hair lacquers.Type: GrantFiled: November 1, 2000Date of Patent: February 25, 2003Assignee: L'Oreal S.A.Inventors: Henri Samain, Christine Dupuis
-
Patent number: 6514482Abstract: A method of pulmonary delivery of a medicament, for example a dopamine precursor or a dopamine agonist, which includes administering to the respiratory tract of a patient in need of rescue therapy particles comprising an effective amount of a medicament. The particles are delivered to the pulmonary system and are released into the blood stream and delivered to the medicament's site of action in a time sufficiently short to provide the rescue therapy. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others. Preferred particles have a tap density of less than about 0.4 g/cm3.Type: GrantFiled: September 19, 2000Date of Patent: February 4, 2003Assignee: Advanced Inhalation Research, Inc.Inventors: Raymond T. Bartus, Dwaine F. Emerich
-
Publication number: 20030007929Abstract: A pharmaceutical topical spray composition of corticosteroid, an alcohol, a propelant, and isopropyl myristate. A method for treating an inflammatory skin condition using the administration to the skin of a mammal of the pharmaceutical composition. The pharmaceutical composition is effective in the treatment of inflammatory skin conditions without the need for zinc pyrithione, undecylenic acid, or a detergent.Type: ApplicationFiled: June 15, 2001Publication date: January 9, 2003Inventor: Charles E. Crutchfield
-
Patent number: 6503481Abstract: A composition used in combination with an electrohydrodynamic device capable of delivering an active ingredient to the aerodigestive system of the user. The composition comprises three or optionally four basic components: an active ingredient; a carrier material in which the active ingredient may be dissolved, suspended, or emulsified; an aerosol properties adjusting material which provides the composition with the physical characteristics required to create an aerosol cloud by electrostatic or electrohydrodynamic means; and optionally at least one excipient that further adjusts, preserves, stabilizes, or enhances the overall performance of the composition.Type: GrantFiled: May 2, 2000Date of Patent: January 7, 2003Assignee: BattellePharma, Inc.Inventors: Rachel M. Thurston, James D. Browning, Praful K. Shah, Michael E. Placke
-
Patent number: 6495120Abstract: A stable formulation is disclosed that enables the effective intra-oral delivery to a patient of a pharmaceutical agent. The formulation comprises the pharmaceutical agent mixed with an orally-acceptable oral-absorption enhancer in an orally-acceptable carrier-solvent, wherein the oral-absorption enhancer is adapted to modify the surface membrane such that absorption through the surface membrane is initiated or increased. The oral-absorption enhancer may comprise hydroxypropyl-beta-cyclodextrin and surfactants including benzalkonium chloride, benzethonium chloride, polysorbate 80, sodium lauryl sulfate, Brij surfactants, Tween and Pluronic surfactants. Also disclosed is a system for delivering the formulation including a mechanism for dispensing predetermined doses of the inventive formulation intra-orally as with an aerosol or spray pump or propellant device.Type: GrantFiled: August 30, 2001Date of Patent: December 17, 2002Inventors: Randall McCoy, Robert O. Williams, III, Miles A. Libbey, III
-
Publication number: 20020187103Abstract: A foaming cosmetic product is provided packaged in a non-aerosol mechanical dispenser. The dispenser includes a container for holding a liquid composition, a dispensing head with a housing enclosing a pump mechanism and a screen material in the flow path to convert liquid composition into a foam, and a diptube for delivering liquid from the container to the dispensing head. The cosmetic composition is an opaque creamy, relatively non-viscous fluid, the creamy appearance imparted by a latex with suspended polymer particles compatible with the foaming mechanism.Type: ApplicationFiled: May 11, 2001Publication date: December 12, 2002Applicant: Unilever Home & Personal Care USA, Division of Conopco, Inc.Inventors: Brian Andrew Crotty, Craig Stephen Slavtcheff, Michael Charles Cheney
-
Patent number: 6488961Abstract: Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g.Type: GrantFiled: December 21, 1999Date of Patent: December 3, 2002Assignee: Ethypharm, Inc.Inventors: Joseph R Robinson, James W. McGinity